|drug2581||Predictors adverse evolution Wiki||1.00|
|drug2760||Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki||0.45|
There is one clinical trial.
1. Objectives: 1.-To create risk stratification scales of poor evolution in patients infected by SARS-CoV-2. 2.-Evaluate the accessibility and equity that these patients have had in the different care processes, diagnostic and therapeutic procedures, with special interest in patients who came from residences, by age, gender or geographic origin.3.-Evaluate the effectiveness of different therapeutic schemes that have been used in this pandemic. 4.-Evaluate the effectiveness of different diagnostic tests used to predict the poor evolution of these patients 5.- Evaluate the real costs associated with the treatment of hospitalized patients with COVID-19 ; 2. Methods: Information will be recorded from electronic medical record: epidemiological data, onset of symptoms, comorbidities and their treatments, symptoms, analytical data, vital signs, tests performed, treatments during admission and evolution up to 3 months after discharge. Statistical analysis: The investigators will use classic survival models, logistic regression, generalized linear models and also analysis using artificial intelligence techniques . Health care costs are assessed. Applications for decision making will be derived as a product.
Description: Clinical deterioration: Resting dyspnoea (Breathing rate > 30 breaths/minute) or 93% oxygen saturation at rest and partial pressure of arterial oxygen ; (PaO2) /Inspired fraction of O2 <300 mm Hg Development of ARDS, sepsis, SIRS, shock entry in ICU(date and days of stay) Decease (date)Measure: Clinical deterioration Time: Admission
Description: Relief of symptoms (days), days until absence of disease (negative test), .Measure: Relief of symptoms Time: Admission
Description: MortalityMeasure: Mortality Time: 6 months
Description: readmissions, clinical complicationsMeasure: Complications at follow up Time: 6 months
Description: Economic costMeasure: Cost Time: Admission
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports